Our previous study demonstrated that AS-IV can reduce the levels of TG and TC, downregulate CD36, and attenuate myocardial dysfunction in diabetic cardiomyopathy rats (Li et al., 2023). Here, CD36 is linked to diabetic cardiomyopathy.